首页 正文

Proteasome and PARP1 dual-target inhibitor for multiple myeloma: Fluzoparib

{{output}}
One of the current mainstream treatments for multiple myeloma (MM) is chemotherapy. However, due to the high clonal heterogeneity and genomic complexity of MM, single-target drugs have limited efficacy and are prone to drug resistance. Therefore, there is an u... ...